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Background: Aldehyde dehydrogenases belong to a superfamily of detoxifying enzymes that protect cells from
carcinogenic aldehydes. Of the superfamily, ALDH1A1 has gained most attention because current studies have
shown that its expression is associated with human cancer stem cells. However, ALDH1A1 is only one of the 19
human ALDH subfamilies currently known. The purpose of the present study was to determine if the expression
and activities of other major ALDH isozymes are associated with human ovarian cancer and ovarian cancer sphere
cultures.
Methods: Immunohistochemistry was used to delineate ALDH isozyme localization in clinical ovarian tissues.
Western Blot analyses were performed on lysates prepared from cancer cell lines and ovarian cancer spheres to
confirm the immunohistochemistry findings. Quantitative reverse transcription-polymerase chain reactions were
used to measure the mRNA expression levels. The AldefluorW assay was used to measure ALDH activity in cancer
cells from the four tumor subtypes.
Results: Immunohistochemical staining showed significant overexpression of ALDH1A3, ALDH3A2, and ALDH7A1
isozymes in ovarian tumors relative to normal ovarian tissues. The expression and activity of ALDH1A1 is tumor
type-dependent, as seen from immunohistochemisty, Western blot analysis, and the AldefluorW assay. The
expression was elevated in the mucinous and endometrioid ovarian epithelial tumors than in serous and clear cell
tumors. In some serous and most clear cell tumors, ALDH1A1 expression was found in the stromal fibroblasts. RNA
expression of all studied ALDH isozymes also showed higher expression in endometrioid and mucinous tumors
than in the serous and clear cell subtypes. The expression of ALDH enzymes showed tumor type-dependent
induction in ovarian cancer cells growing as sphere suspensions in serum-free medium.
Conclusions: The results of our study indicate that ALDH enzyme expression and activity may be associated with
specific cell types in ovarian tumor tissues and vary according to cell states. Elucidating the function of the ALDH
isozymes in lineage differentiation and pathogenesis may have significant implications for ovarian cancer
pathophysiology.
Keywords: Aldehyde dehydrogenase, Isozymes, Ovarian tumors, Sphere cultures, Tumor-type specific expression* Correspondence: sng@rics.bwh.harvard.edu
1Department of Obstetrics/Gynecology and Reproductive Biology, Brigham
and Women’s Hospital, Boston, MA 02115, USA
Full list of author information is available at the end of the article
© 2012 Saw et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Saw et al. BMC Cancer 2012, 12:329 Page 2 of 12
http://www.biomedcentral.com/1471-2407/12/329Background
Ovarian cancer accounts for more than half of the deaths
due to gynecological malignancy [1]. There were an esti-
mated 14,000 deaths in 2010, thus making it the 5th most
common cause of cancer death among women in the Uni-
ted States [2]. As most of the ovarian cancer patients are
diagnosed in late stage and 80% of the patients recur des-
pite successful surgery and chemotherapy, the 5-year sur-
vival rate is only 30% [3]. Hence, specific and sensitive
screening programs and identification of targets that are
central to ovarian pathogenesis are of paramount value in
decreasing the mortality of ovarian cancer.
Epithelial ovarian cancer is a tumor with great diver-
sity. According to World Health Organization (WHO)
criteria, ovarian tumors can be classified as benign, low
malignant potential (borderline), or malignant [4]. The
histologic classification of ovarian carcinomas is based
on morphologic criteria and corresponds to the different
types of epithelia in the female reproductive system [5].
There are four major histologic subtypes of epithelial
ovarian cancer [4]. Serous tumors are the most common
type of ovarian neoplasm with epithelial cells resembling
those of fallopian tube and comprise about 50% of pri-
mary epithelial ovarian tumors. Mucinous tumors repre-
sent 12-15% of epithelial ovarian cancers. They are
cystic tumors with locules lined with mucin-secreting
epithelial cells resembling either endocervical or colonic
epithelium. Recent studies have shown that some mu-
cinous ovarian tumors can be misdiagnosed due to me-
tastasis from other organs [6]. Endometrioid and clear
cell tumors each account for 10% of epithelial ovarian
cancers. These tumors are thought to arise from foci of
endometriosis and endometriotic cysts within the ovary
[7,8]. Different tumor subtypes are characterized by dys-
regulation in specific pathways and have important ramifi-
cations in disease prognosis and treatment response
[9–11]. Unfortunately, the molecular mechanisms under-
lying ovarian carcinogenesis and histological differenti-
ation remain elusive.
The cancer stem cell (CSC) model hypothesizes the
presence of a cellular hierarchy in the tumors such that
a subset of tumor cells have the ability to self-renew and
generate the diverse cells that comprise the tumor [12].
CSCs may therefore be responsible for continual sustain-
ment of tumorigenesis, as well as multilineage differenti-
ation into different types of tumors. However, it is
difficult to definitively identify cell surface immunophe-
notypes representing CSCs and their progeny in solid
tumors. The cell surface biomarkers described thus far
for the same tumor types are found highly variable by
different research groups [13–15]. Recently there have
been reports showing that differentiated cells can ac-
quire self-renewing capacity [12,16] and stem-like cancer
cells arise de novo from non-stem cells in vitro andin vivo [17,18], suggesting bidirectional interconversions
between stem and non-stem compartments. Perturb-
ation of the cell-state dynamics by genetic or pharmaco-
logical methods has the potential to change the
proportions of subpopulations of cells. Hence, it is likely
that the “stemness” of a tumor and its response to thera-
peutic manipulation depends on the stochastic state
equilibrium in the populations of cancer cells. The
sphere assay discovered in early stem cell studies relies
on the capability of stem cells to form spheres when cul-
tured in serum-free medium with growth factors to
maintain the undifferentiated state [19]. Mammospheres
formed by human mammary epithelial cells exhibit char-
acteristics of early progenitor/stem cells and are able to
differentiate along all three mammary epithelial lineages
and develop complex functional mammary structures.
Tumor sphere cells have recently been widely adopted
as an in vitro model to study CSCs for human cancers
[20–24]. The sphere cells possess self-renewal capacity,
with continuous capacity of the dissociated single cells
to form secondary spheres. Lower numbers of sphere
cells than bulk cancer cells are sufficient to form tumors
when transplanted into non-obese diabetic-severe com-
bined immunodeficient (NOD-SCID) mice and show
great metastatic capacity [20–24].
Many of the sphere cells and stem cells reported in dif-
ferent systems have been found to be associated with ele-
vated ALDH1A1 enzyme activity as measured by a
commercially available kit, AldefluorW [20,25,26]. Positive
correlations between ALDH1A1 enzyme activity and ex-
pression are apparent [27], indicating that ALDH1A1 ex-
pression or activity may be used with other cell surface
markers to identify tumor-initiating cells in hepatocellular,
prostate and breast solid carcinomas [28–30]. ALDH1A1
expression has been found to be associated with early me-
tastasis and poor clinical outcome [26]. Aldehyde de-
hydrogenase (ALDH) proteins are a superfamily of 19
enzymes that are found to protect cells from cytotoxic
and carcinogenic aldehydes in various organelles including
the nucleus, cytosol, mitochondria, and endoplasmic
reticulum [31,32]. The ALDH enzymes also play a crucial
role in epithelial homeostasis. Thus, deregulation of these
enzymes is linked to multiple cancers, such as breast,
prostate, lung and colon cancers [33–37]. In this study, we
aimed to investigate if the expression of ALDH isozymes
varied among different histological subtypes of ovarian
tumor tissues. Our focus was on ALDH class 1, 3 and 7
isozymes, all of which have been reported to be associated
with cancer development [28,33–35]. Moreover, as a pre-
liminary approach to explore the potential association be-
tween these ALDH isozymes and cancer cells in stem-like
state, we have also investigated the expression levels of
these ALDH isozymes in ovarian cancer cells growing as
spheres in serum-free medium.
Table 2 ALDH3A2 immunohistochemical staining
according to diagnosis and histological characteristics of
the epithelial and stromal components of ovarian
samples
Characteristics n a epithelial stromal
score b P c C.I. d score b P c
Diagnosis
healthy 5 0.94 ± 0.38 0.003* reference 1.90 ± 0.74 0.1*
benign 4 3.81 ± 1.84 (−1.0, 6.7) 2.25 ± 1.50
borderline 3 4.42 ± 0.63 (−0.7, 7.7) 1.83 ± 2.02
invasive 35 5.59 ± 2.60 (1.9, 7.4)** 1.00 ± 0.88
Histology
serous 17 5.44 ± 2.86 0.31 1.09 ± 0.87 0.74
mucinous 6 5.75 ± 1.17 0.92 ± 1.16
endometrioid 5 7.50 ± 2.60 0.65 ± 0.78
clear cell 6 4.54 ± 2.75 1.21 ± 0.87
a Number of cases.
b Immunohistochemistry staining score expressed as mean ± SD.
c P-value, ANOVA test of equal means among the four groups (* equal
population variances assumption did not meet, corresponding p-value using
Kruskal-Wallis test for equal medians was displayed).
d Two-sided 95% confidence interval (C.I.) for the difference in means,
Dunnett’s post-hoc test compared to value in healthy (in Diagnosis group) or
clear cell (in Histology group) as the “reference” group. Dunnett’s test was
performed only when the ANOVA or Kruskal-Wallis result was significant
(p < 0.05).
** Significant based on Dunnett’s test (family error rate set to 0.05).
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Type-specific expression of ALDH isozymes
We first employed immunohistochemistry to investigate
the expression levels of the different ALDH isozymes in
archived ovarian tissues using isozyme-specific anti-
bodies. Antibodies specific to ALDH1A1, ALDH1A3,
ALDH3A1, ALDH3A2, ALDH3B1 and ALDH7A1 were
used to stain a panel of healthy ovaries, benign, border-
line, and invasive ovarian tumors. The clinicopathologic
characteristics of the samples we used are shown in
Additional file 1: Table S1. We found significantly ele-
vated expression of ALDH1A3 (Table 1), ALDH3A2
(Table 2), and ALDH7A1 (Table 3) in the epithelial ovar-
ian tumor tissues than healthy ovarian epithelia. Mul-
tiple comparisons using Dunnett’s method showed that
there were significant differences between normal ovar-
ies and invasive tumors for ALDH3A2 and ALDH7A1,
whereas ALDH1A3 staining showed significant differ-
ences between normal ovaries and both borderline and
invasive tumors. There was no significant difference in
the staining for ALDH isozymes in normal, benign, and
tumor stromal components. There was no positive stain-
ing from the ALDH3A1 antibody, and the staining of
ALDH3B1 did not show significant differences between
healthy ovaries and ovarian tumor tissues (data not
shown). Differences between histologic tumor subtypes
for ALDH1A3, ALDH3A2, and ALDH7A1 were notTable 1 ALDH1A3 immunohistochemical staining
according to diagnosis and histological characteristics of
the epithelial and stromal components of ovarian
samples
Characteristics n a epithelial stromal
score b P c C.I. d score b P c
Diagnosis
healthy 4 0.13 ± 0.25 0.02* reference 0.13 ± 0.25 0.27
benign 3 3.25 ± 0.43 (-0.8, 7.0) 1.58 ± 1.38
borderline 3 4.92 ± 2.63 (0.9, 8.7)** 0.75 ± 0.66
invasive 19 4.28 ± 2.24 (1.3, 7.0)** 0.70 ± 0.98
Histology
serous 8 3.88 ± 2.84 0.47 0.91 ± 1.31 0.73
mucinous 3 5.00 ± 0.00 0.92 ± 1.16
endometrioid 4 5.56 ± 1.59 0.25 ± 0.00
clear cell 4 3.25 ± 2.06 0.56 ± 0.63
a Number of cases.
b Immunohistochemistry staining score expressed as mean ± SD.
c P-value, ANOVA test of equal means among the four groups (* equal
population variances assumption did not meet, corresponding p-value using
Kruskal-Wallis test for equal medians was displayed).
d Two-sided 95% confidence interval (C.I.) for the difference in means,
Dunnett’s post-hoc test compared to value in healthy (in Diagnosis group) or
clear cell (in Histology group) as the “reference” group. Dunnett’s test was
performed only when the ANOVA or Kruskal-Wallis result was significant
(p < 0.05).
** Significant based on Dunnett’s test (family error rate set to 0.05).
Table 3 ALDH7A1 immunohistochemical staining
according to diagnosis and histological characteristics of
the epithelial and stromal components of ovarian
samples
Characteristics n a epithelial stromal
score b P c C.I. d score b P c
Diagnosis
healthy 5 0.64 ± 0.47 0.005* reference 1.70 ± 0.45 0.54
benign 4 2.63 ± 2.29 (-2.2, 6.2) 3.75 ± 0.50
borderline 3 4.58 ± 1.44 (-0.6, 8.5) 3.00 ± 1.00
invasive 40 5.36 ± 2.77 (1.8, 7.7)** 3.27 ± 2.67
Histology
serous 18 4.57 ± 3.09 0.34 2.87 ± 2.53 0.08
mucinous 8 6.44 ± 2.46 5.43 ± 1.86
endometrioid 8 5.88 ± 2.58 1.70 ± 1.75
clear cell 5 6.20 ± 1.79 3.25 ± 4.03
a Number of cases.
b Immunohistochemistry staining score expressed as mean ± SD.
c P-value, ANOVA test of equal means among the four groups (* equal
population variances assumption did not meet, corresponding p-value using
Kruskal-Wallis test for equal medians was displayed).
d Two-sided 95% confidence interval (C.I.) for the difference in means,
Dunnett’s post-hoc test compared to value in healthy (in Diagnosis group) or
clear cell (in Histology group) as the “reference” group. Dunnett’s test was
performed only when the ANOVA or Kruskal-Wallis result was significant
(p < 0.05).
** Significant based on Dunnett’s test (family error rate set to 0.05).
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ple sizes in these experiments and subtle changes may
not be detected. Representative figures of the immuno-
histochemical staining of ALDH1A3, ALDH3A2, and
ALDH7A1 antibodies to different categories of tissues
are shown in Figure 1.
Initial immunohistochemical staining of the stem cell
marker ALDH1A1 in ovarian tissues yielded particularlyFigure 1 Expression of ALDH1A3, ALDH3A2, and ALDH7A1 in archive
staining of A. ALDH1A3; B. ALDH3A2; and C. ALDH7A1 in ovarian tissues. Binteresting patterns not seen with the other ALDH iso-
zymes described above. We have therefore added more
cases to confirm the initial findings and the final results
are presented here. The staining was not significantly
different between healthy ovaries and ovarian tumors
(Table 4). However, we saw significant differences in the
expression between the different histologic subtypes of
ovarian tumors. The endometrioid and mucinous tumorsd ovarian tissues. Representative figures of immunohistochemical
OT, borderline tumors. Scale bar represents 50 μm.
Table 4 ALDH1A1 immunohistochemical staining according to diagnosis and histological characteristics of the
epithelial and stromal components of ovarian samples
Characteristics n a epithelial stromal
score b P c C.I. d score b P c C.I. d
Diagnosis
healthy 5 0.15 ± 0.22 0.102 0.60 ± 0.82 0.08
benign 4 1.94 ± 2.96 4.44 ± 3.14
borderline 8 3.78 ± 3.37 1.94 ± 1.92
invasive 101 1.66 ± 2.71 1.85 ± 2.25
Histology
serous 40 0.67 ± 1.52 < 0.001* (-0.8, 1.5) 1.12 ± 1.28 0.02 (-3.1, -0.5)**
mucinous 12 5.65 ± 3.05 (3.7, 7.0)** 1.98 ± 2.17 (-2.7, 0.9)
endometrioid 19 3.38 ± 3.28 (1.6, 4.5)** 1.76 ± 2.70 (-2.7, 0.4)
clear cell 29 0.31 ± 0.45 reference 2.90 ± 2.74 reference
a Number of cases.
b Immunohistochemistry staining score expressed as mean ± SD.
c P-value, ANOVA test of equal means among the four groups (* equal population variances assumption did not meet, corresponding p-value using Kruskal-Wallis
test for equal medians was displayed).
d Two-sided 95% confidence interval (C.I.) for the difference in means, Dunnett’s post-hoc test compared to value in healthy (in Diagnosis group) or clear cell (in
Histology group) as the “reference” group. Dunnett’s test was performed only when the ANOVA or Kruskal-Wallis result was significant (p < 0.05).
** Significant based on Dunnett’s test (family error rate set to 0.05).
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cells, whereas serous and clear cell epithelial tumor tissues
showed very low ALDH1A1 expression (P < 0.001).
Dunnett’s multiple comparisons showed significantly
lower expression of ALDH1A1 in clear cell tumors than
in mucinous and endometrioid tumor types. While the
epithelial clear cell tumor cells showed lower ALDH1A1
expression than the other tumor types, ALDH1A1 ex-
pression was higher in the clear cell stromal fibroblasts
than in the other stromal tumor types (P = 0.02). Figure 2
shows representative images of ALDH1A1 in the dif-
ferent ovarian tissues and in particular the absence of
ALDH1A1 staining in the tumors but increased stain-
ing in the stromal part of eighteen clear cell ovarian
tumors.
To evaluate the tumor type-specific expression of
ALDH isozymes, we also performed quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) to
measure the mRNA expression levels of ALDH1A1,
ALDH1A3, ALDH1B1, ALDH3A1, ALDH3A2, ALDH3B1
and ALDH7A1 in tumor cells microdissected from a
panel of frozen tumor tissues. Boxplot in Figure 3 shows
that, in general, the RNA levels of all ALDH isozymes
were significantly higher in both endometrioid and mu-
cinous tumors than in clear cell and serous tumors. The
RNA expression patterns resemble the protein expres-
sion of ALDH1A1, which shows higher expression in the
endometrioid and mucinous tumors compared with
clear cell and serous tumors. However, as ALDH1A3,
ALDH3A2 and ALDH7A1 isozymes did not show particu-
larly significant tumor-type specific protein expression,
there might be other post-transcriptional mechanisms thatregulate the different ALDH isoenzyme protein levels in
the tumor tissues.
Western blot analysis was performed to evaluate the
expression of the ALDH isozymes in ovarian cell lines.
As illustrated in Figure 4A, most of ALDH isozymes ex-
cept ALDH1A3 showed higher levels in the ovarian can-
cer cell lines relative to the normal human ovarian surface
epithelial (HOSE) cell lines. Only OVCA433 and MCAS
showed higher level of ALDH1A3 expression. Like the
immunohistochemical staining results in tumor tissues,
ALDH1A1 showed a strong tumor type-dependence in
expression pattern. While endometrioid and mucinous
cancer cell lines showed high protein expression, the
serous and clear cell cell lines showed little, if any, de-
tectable protein expression. It is noted that as we have
only one endometrioid cancer cell line, the result may
not reflect broadly this histologic subtype.
Expression and activity of ALDH1A1 in ovarian cancer
cells growing as sphere suspension
The immunohistochemistry and Western blot results led
us to further investigate ALDH1A1 as a potential stem
cell marker by evaluating the expression of this protein
in ovarian cancer spheres. The sphere assay, which
demonstrates the capability of stem-like cells to form
spheres when cultured in serum-free medium with
growth factors [19], has been widely adopted as an
in vitro model to study CSCs for human cancers
[20–24]. We performed sphere assays with ovarian epi-
thelial cancer cells by growing them as sphere suspensions
in standard serum-free medium. We used Western blot
analysis to compare the expression of ALDH1A1 and
Figure 2 Expression of ALDH1A1 in archived ovarian tissues. A. Representative figures of immunohistochemical staining of ALDH1A1 in
normal ovaries and different subtypes of ovarian tumor tissues. B. Extended panel of fifteen clear cell ovarian tumor samples stained with
ALDH1A1 to demonstrate the predominant staining in the stromal fibroblasts. Scale bar represents 50 μm.
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suspension versus growing as monolayer in complete
medium. ALDH7A1 protein expression showed a slight
increase in the spheres formed by endometrioid and mu-
cinous cancer cell lines than in the monolayer cells. For
ALDH1A1 expression, the two mucinous cancer lines
showed increase in expression in sphere cultures than
monolayer cultures. The endometrioid cancer cell line
expressed very high level of ALDH1A1 both in sphere and
monolayer cultures. The clear cell cancer cell line showed
some increase from the monolayer cells to the sphere
cells. In contrast, serous cancer cell lines did not showany increase in ALDH1A1 expression in the spheres
(Figure 4B).
In addition to the protein expression analyses, the
AldefluorW assay was used to measure specific ALDH
activity in the monolayer and sphere cancer cells. Repre-
sentative results, shown in Figure 5, are parallel the
results obtained by Western blot analysis. The mucinous
cancer cells showed robust increased activity in the
sphere cells. Endometrioid cells showed strong ALDH
activity under both monolayer and sphere conditions.
The clear cell cancer cells showed a small increase in ac-
tivity in the sphere cells, while the serous cancer cells
C E M S C E M S C E M S C E M S C E M S C E M S C E M S
ALDH1A1 ALDH1A3 ALDH1B1 ALDH3A1 ALDH3A2 ALDH3B1 ALDH7A1

















Figure 3 Boxplot to show the quantitative reverse transcription-polymerase chain reaction results of ALDH isozymes in the ovarian
cancer cells present in different subtypes of ovarian tumor tissues. RNA was extracted from tumor cells microdissected from 19 high-grade
serous, 5 mucinous, 6 clear cell, and 5 endometrioid tumor tissues and quantitative reverse transcription-polymerase chain reactions were
performed. Each box covers the middle 50% of ranks of ordered expression of the corresponding ALDH isozyme, and the horizontal line within a
box marks the median. The lines extending from a box reach to the minimum and maximum data values, except the presence of outliers that
are marked with an asterisk. Kruskal-Wallis P-values are presented to indicate whether the median ranks of the ALDH isozymes are significantly
different among the four histologic groups. C, clear cell ovarian tumors; E, endometrioid ovarian tumors; M, mucinous ovarian tumors; S, serous
ovarian tumors.
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ALDH activity under either culture conditions. Although
other studies have suggested that the AldefluorW assay
also measures the activity of some other ALDH isoforms
such as ALDH1A3 [34,36], our AldefluorW assay results
closely reflect the ALDH1A1 activity in the cancer cells.
Implications of ALDH isozyme expression in ovarian
cancer
Ovarian cancer is heterogeneous in nature, comprising
tumors with different histologic subtypes and develop-
mental stages [4,5]. The cancer stem cell hypothesis pro-
poses the presence of distinct tumor-propagating cell
populations that are responsible for self-renewal and mul-
tilineage differentiation into different types of tumors [12].
ALDH1A1, and recently ALDH1A3, have been described
as valuable stem cell markers in different human tumors
and in vitro systems [26,28,34,36]. ALDH1A1 positivity
has also been associated with chemoresistance in ovarian
cancer [38,39]. The present study revealed ALDH1A1 to
be expressed predominantly in mucinous and endome-
trioid epithelial cancer cells, but not in most of the serous
and clear cell cancer cells. Instead, high ALDH1A1 ex-
pression was found in the stromal fibroblasts in the latter
two types of ovarian cancer. In a previous study, higher
levels of ALDH1A1 expression were found in mammary
stromal cells than in epithelial cells [40]. Although it
might be argued that the stromal ALDH1A1 staining
arose from cancer cells with mesenchymal features, as
suggested in a proteomic profiling study of a panel of lung
adenocarcinoma cell lines [37], the predominant stromalstaining observed in our study is consistent with
ALDH1A1 expression being distinctly lineage-specific in
different histologic types of ovarian tumors. It is well
documented that expression and activity levels of ALDH
isozymes depend on cancer type and/or cell of origin
[36,40]. Penumatsa et al... reported recently reduced
expression of ALDH1A1 in serous ovarian tumors [41]
and Li et al... reported that ALDH1A1 expression was
repressed by histone-lysine N-methyltransferase EZH2
in high-grade serous ovarian carcinomas [42]. It will be
of great interest to delineate the role of ALDH1A1 in
lineage differentiation and its regulation in ovarian
cancer.
Moreover, it is of equal importance to evaluate the
functional roles of elevated ALDH1A3, ALDH3A2 and
ALDH7A1 isozymes in ovarian cancer. The ALDH1A3
isoform has been reported to be a novel CSC marker
with potential clinical prognostic application in breast
cancer [34]. ALDH7A1 was also found to be involved in
prostate cancer bone metastasis [33]. Further analysis of
these novel ALDH isozymes may have significant diag-
nostic and prognostic implications in ovarian cancer. A
more thorough understanding of the molecular mechan-
isms underlying their activities in the development of
ovarian cancer may pave a way for more effective treat-
ment of ovarian cancer.
Conclusions
We have performed an analysis of the expression of dif-
ferent ALDH isozymes in ovarian tumors and cancer cell
lines. ALDH1A1 shows a tumor type-specific expression
Figure 4 ALDH isozyme protein expression in ovarian cell lines. A. Western blot analysis was used to compare the expression of different
ALDH isozymes in normal human ovarian surface epithelial (HOSE) cell lines with cancer cell lines of different subtypes, i.e., serous, endometrioid
(ENDO), mucinous (MUC) and clear cell (CC). The cell lines were (starting from left): HOSE1-15, HOSE7, HOSE2170, SKOV3, OVCA432, OVCA433,
TOV112D, MCAS, RMUGL, RMG1, and OVCA810. Molecular weights are shown on the right. β-actin served as loading control. B. Western blot
analysis was used to compare the levels of ALDH1A1 and ALDH7A1 in ovarian cancer cell lines growing as a monolayer (2D) or sphere culture.
The cell lines were (starting from left): RMG1, MCAS, RMUGL, OVCA432, SKOV3, and TOV112D. β-actin served as loading control.
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entiation mechanisms during histopathologic develop-
ment of ovarian tumors. Further studies are required to
elucidate the roles ALDH1A1 and other elevated ALDH
isozymes play in ovarian pathogenesis.
Methods
Ovarian clinical samples and ovarian cell lines
Archived formalin-fixed, paraffin-embedded normal, be-
nign, and cancerous ovarian tissues were collected from
women undergoing surgery at the Brigham and
Women's Hospital for a diagnosis of primary ovarian
cancer or from control subjects who were undergoing
the procedure of hysterectomy or oophorectomy for be-
nign gynecologic diseases. Additional 15 cases of clear
cell ovarian carcinomas were from Department of
Obstetrics and Gynecology, Osaka City GeneralHospital, Japan. All patient-derived biologic specimens
were collected and archived under protocols approved
by the Human Subjects Committee of the Brigham and
Women's Hospital, USA, and Osaka City General Hos-
pital, Japan. Samples were collected with written
informed consent from patients and confirmed histologi-
cally by gynecologic pathologists. Cases were staged
according to International Federation of Gynecology and
Obstetrics (FIGO) system. The normal human ovarian
surface epithelial (HOSE) cells and ovarian cancer cell
lines have been described previously [43]. Normal HOSE
cells were collected by scraping the ovarian surface of
the control subjects who were undergoing hysterectomy
or oophorectomy for benign diseases. Long-term HOSE
cells were immortalized by a HPV E6/E7 gene introduc-
tion. All ovarian cell lines were maintained in a mixture
of medium 199 and MCDB105 medium (1:1) (Sigma, St.
Figure 5 ALDH activity in cancer cells under different culture growing conditions. AldefluorW was used to estimate ALDH enzyme activity
in cells grown as a monolayer culture or in a sphere culture. Flow cytometric graphs show the fluorescence intensity of reacted ALDH substrate
in the absence and presence of diethylaminobenzaldehyde, a specific ALDH inhibitor, for A: endometrioid cancer cell line TOV112D; B: Clear cell
cancer cell line RMG1; C. Mucinous cancer cell line RMUGL, and D: high-grade serous cancer cells isolated from clinical ascites. Gated regions
indicated ALDH+ cells.
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(Invitrogen, Carlsbad, CA).
Sphere assay
Standard sphere assay was performed according to
Dontu et al. . . with minor changes [19]. Single cancer
cells were resuspended in NeuroBasal-A Medium (Invi-
trogen) supplemented with B27 (Invitrogen), 20 ng/mlEGF and 20 ng/ml bFGF (Invitrogen), and 4 μg/ml hep-
arin (Sigma-Aldrich), in ultra-low attachment culture
plates (Fisher Scientific, Pittsburgh, PA). Cells were cul-
tured for 1 week to form spheres before harvesting.
Immunohistochemistry
Paraffin-embedded ovarian tissue blocks were sectioned
at a thickness of 7 μm, mounted on Superfrost Plus
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and dried at 50 °C for at least 3 hours. Deparaffinization
was performed using xylene and rehydration with a
graded ethanol series. Antigen retrieval was performed
in a pressure-cooker in antigen-unmasking solution
(Vector Laboratories, Burlingame, CA) for 10 min. En-
dogenous peroxidases were blocked using 0.3%H202 in
methanol for 20 min. The sections were then blocked
with normal blocking serum for 20 min and subse-
quently incubated overnight with ALDH isozyme-
specific antibodies. Antibodies specific to ALDH1A1,
ALDH1A3, ALDH3A1, ALDH3A2, and ALDH3B1 have
been described [44,45]. Antibody specific to ALDH7A1
was purchased from Epitomics, Inc (Burlingame, CA).
After incubations with primary and secondary antibodies
(Vector Laboratories, Burlingame, CA), the reaction was
visualized using Vectastain Elite ABC Kit with diamino-
benzidine chromogen as a substrate (Vector Laborator-
ies, Burlingame, CA). Sections were counterstained
lightly with hematoxylin and mounted in PermountW
(Fisher Scientific, Pittsburgh, PA). The staining was
quantified with a semi-quantitative scoring system. The
weighted score was obtained by multiplying the staining
intensity score ranging from 3+ (strongest positive) to 0
(no evidence of stain) and the score for the percentage
of positive cells ranging from 3+ (100% stained) to 0
(no cells stained). Two trained observers scored the
slides independently and the scores were compared for
discrepancies and averaged.RNA isolation and quantitative reverse transcription-
polymerase chain reaction
Microdissection of ovarian tumor cells from frozen tis-
sues (19 high-grade serous, 5 mucinous, 6 clear cell, and
5 endometrioid) was performed using a MD LMD laser
microdissecting microscope (Leica Microsystems, Buffalo
Grove, IL). Note that these samples were not the same
samples used in the immunohistochemical study. Total
RNA was isolated using RNeasy Micro Kit (Qiagen,









Cyclophilin A 5'-CTGGACCCAACACAAATGGTT-3'were performed using High Capacity cDNA Reverse Tran-
scription Kit and SYBRW Green PCR kit, respectively
(Invitrogen Life Technologies,Carlsbad, CA). The primers
for different ALDH isozymes are listed in Table 5. To cal-
culate the relative expression for each gene, the 2−ΔΔCT
method was used to relate the CT values of ALDH expres-
sion in each sample to the CT values for the housekeeping
gene cyclophilin A [46].Western blot analysis
Total cell lysates were prepared from growing cells using
RIPA buffer (50 mM Tris–HCl pH 8, 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate and 0.1% SDS) sup-
plemented with PhosStop phosphatase inhibitor cocktail
and complete protease inhibitor cocktail (Roche Applied
Science, Indianapolis, IN) and protein concentration was
measured with a MicroBCA protein assay kit (Thermo-
Scientific, Rockford, IL). Ten μg of total cell lysates were
resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to a polyvi-
nylidene fluoride (PVDF) membrane using a SEMI-DRY
Transfer cell (Bio-Rad Laboratories, Hercules, CA). After
blocking with 5% nonfat dry milk in 1X TBST buffer
(10 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.05%
Tween-20) at room temperature for 1 hr, the membrane
was incubated with the primary antibody at 4°C over-
night, then washed at room temperature with 1X TBST
buffer. The bound antibody was detected by the second-
ary antibodies conjugated with horseradish peroxidase
(Pierce Biotechnology, Rockford, IL) and a Supersignal
west pico kit (Pierce Biotechnology, Rockford, IL).AldefluorW assay
ALDH activity was detected using the AldefluorW assay
kit (STEMCELL Technologies, Vancouver, BC, Canada)
as described by the manufacturer. Briefly, dissociated
single cells from cell lines or spheres were resuspended
in AldefluorW assay buffer containing an ALDH sub-
strate, bodipy-aminoacetaldehyde (BAAA), at 7.5 μM,
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minobenzaldehyde (DEAB), an ALDH-specific inhibitor.
Fluorescence intensity of the stained cells was analyzed
using an Accuri C6 Flow Cytometer (BD Accuri Cyt-
ometers, Ann Arbor, MI). The reaction with DEAB was
used to define the baseline for the assay, i.e., fluores-
cence not associated with ALDH activity. ALDH activity
of a sample was determined based on the fluorescence
intensity beyond the threshold defined by the reaction
with DEAB.
Statistical Analysis
All analyses were performed using MINITAB statistical
software (Minitab, State College, PA). ANOVA was used
to compare the mean IHC scores among different diag-
nostic and histologic groups. If the equal population var-
iances assumption was not met, the non-parametric
Kruskal-Wallis test was performed to compare the results
obtained from ANOVA. When there was a statistically sig-
nificant difference among the groups, multiple compari-
sons with a control group (Healthy group for Diagnosis
and Clear Cell group for Histology) were performed using
the Dunnett’s method. A difference was deemed signifi-
cant when it reached the 5% level, i.e., P≤ 0.05. As the nor-
mality assumption for the qRT-PCR data was not met, the
Kruskal-Wallis test was used to analyze the ranked qRT-
PCR data according to histologic subtypes, and the results
are presented as a boxplot.
Additional file
Additional file 1: Table S1.
Competing interests
The authors declare that they have no competing interests to disclose.
Authors’ contributions
Y-TS, MS carried out the immunohistochemistry. JY carried out Western blot
analysis, RT-PCR and sphere cultures. SL performed AldefluorW assays and
analysis. SS participated in the RT-PCR. S-KN performed statistical analysis.
Y-TS, DT, and S-KN helped draft the manuscript. HT, WRW, VV, and RSB
contributed the samples and reagents and critically revised the manuscript.
W-PF participated in the design of the study. S-WN conceived, participated
in study design and coordination and wrote the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
We acknowledge the support of the Robert and Deborah First Fund, the
Sperling Family Fund Foundation, Ruth N. White Gynecologic Oncology
Research Fund, Women’s Cancer Program and Gillette Center for Women’s
Cancer from Dana-Farber Cancer Institute, Ovarian Cancer Research
Foundation, Adler Foundation, Inc., and the Friends of Dana Farber Cancer
Institute to The Laboratory of Gynecologic Oncology.
Author details
1Department of Obstetrics/Gynecology and Reproductive Biology, Brigham
and Women’s Hospital, Boston, MA 02115, USA. 2School of Medicine, Griffith
Health Institute, Griffith University, Meadowbrook, QLD 4131, Australia.
3Department of Pharmaceutical Sciences, University of Colorado Denver,
Aurora, CO 80045, USA. 4Department of Pathology, Brigham and Women’sHospital, Boston, MA 02115, USA. 5Department of Obstetrics and Gynecology,
School of Medicine, Keio University, Tokyo 160-8582, Japan. 6School of Life
Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Received: 9 April 2012 Accepted: 18 July 2012
Published: 1 August 2012References
1. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J,
Howlader N, Tatalovich Z, Cho H, et al: SEER Cancer Statistics Review, 1975–
2007. Bethesda, MD, USA: National Cancer Institue; 2010.
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60(5):277–300.
3. Bast RC Jr, Boyer CM, Olt GJ, Berchuck A, Soper JT, Clarke-Pearson D, Xu FJ,
Ramakrishnan S: Identification of marker for early detection of epithelial
ovarian cancer. London, England: Chapman and Hall Medical; 1990.
4. Serov SF, Scullt RE: Histological typing of ovarian tumors, Volume 9. Geneva:
World Health Organization; 1993.
5. Thor AD, Young RH, Clement PB: Pathology of the fallopian tube, broad
ligament, peritoneum, and pelvic soft tissues. Hum Pathol 1991,
22(9):856–867.
6. McCluggage WG, Wilkinson N: Metastatic neoplasms involving the ovary:
a review with an emphasis on morphological and immunohistochemical
features. Histopathology 2005, 47(3):231–247.
7. Cambell IG, Morland S, Hitchcock A: Endometriosis and the relationship with
ovarian cancer., vol. 5. Oxford: ISIS Medical Media Ltd; 1998.
8. DePriest PD, Banks ER, Powell DE, van Nagell JR Jr, Gallion HH, Puls LE,
Hunter JE, Kryscio RJ, Royalty MB: Endometrioid carcinoma of the ovary
and endometriosis: the association in postmenopausal women. Gynecol
Oncol 1992, 47(1):71–75.
9. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW,
Nikrui N, Tamimi HK, Cain JM, Greer BE, et al: Clear cell carcinoma of the
ovary: a distinct histologic type with poor prognosis and resistance to
platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996, 60
(3):412–417.
10. Recio FO, Piver MS, Hempling RE, Driscoll DL: Lack of improved survival
plus increase in thromboembolic complications in patients with clear
cell carcinoma of the ovary treated with platinum versus nonplatinum-
based chemotherapy. Cancer 1996, 78(10):2157–2163.
11. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N: Low
proliferation activity may be associated with chemoresistance in clear
cell carcinoma of the ovary. Obstet Gynecol 2002, 100(2):281–287.
12. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours:
accumulating evidence and unresolved questions. Nat Rev Cancer 2008,
8(10):755–768.
13. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ,
Heeschen C: Distinct populations of cancer stem cells determine tumor
growth and metastatic activity in human pancreatic cancer. Cell Stem Cell
2007, 1(3):313–323.
14. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A,
Huang EH, Simeone DM, et al: Phenotypic characterization of human
colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007,
104(24):10158–10163.
15. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L:
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with
cancer stem cell characteristics. Breast Cancer Res 2008, 10(1):R10.
16. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M,
Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal
transition generates cells with properties of stem cells. Cell 2008, 133
(4):704–715.
17. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander
ES: Stochastic state transitions give rise to phenotypic equilibrium in
populations of cancer cells. Cell 2011, 146(4):633–644.
18. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO,
Brooks M, Reinhardt F, Su Y, Polyak K, et al: Normal and neoplastic
nonstem cells can spontaneously convert to a stem-like state. Proc Natl
Acad Sci U S A 2011, 108(19):7950–7955.
19. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ,
Wicha MS: In vitro propagation and transcriptional profiling of human
mammary stem/progenitor cells. Genes Dev 2003, 17(10):1253–1270.
Saw et al. BMC Cancer 2012, 12:329 Page 12 of 12
http://www.biomedcentral.com/1471-2407/12/32920. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur
MH, Diebel ME, Monville F, Dutcher J, et al: Breast cancer cell lines contain
functional cancer stem cells with metastatic capacity and a distinct
molecular signature. Cancer Res 2009, 69(4):1302–1313.
21. Bortolomai I, Canevari S, Facetti I, De Cecco L, Castellano G, Zacchetti A,
Alison MR, Miotti S: Tumor initiating cells: Development and critical
characterization of a model derived from the A431 carcinoma cell line
forming spheres in suspension. Cell Cycle 2010, 9(6):1194–1206.
22. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H: Lin-Sca-
1 +CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-
null prostate cancer model. Cancer Res 2009, 69(22):8555–8562.
23. Lukacs RU, Lawson DA, Xin L, Zong Y, Garraway I, Goldstein AS,
Memarzadeh S, Witte ON: Epithelial stem cells of the prostate and their
role in cancer progression. Cold Spring Harb Symp Quant Biol 2008,
73:491–502.
24. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ,
Mayo JG, Shoemaker RH, Boyd MR: Feasibility of drug screening with panels
of human tumor cell lines using a microculture tetrazolium assay. Cancer
Research 1988, 48(3):589–601.
25. Carpentino JE, Hynes MJ, Appelman HD, Zheng T, Steindler DA, Scott EW,
Huang EH: Aldehyde dehydrogenase-expressing colon stem cells
contribute to tumorigenesis in the transition from colitis to cancer.
Cancer Res 2009, 69(20):8208–8215.
26. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B,
Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, et al: Aldehyde
dehydrogenase 1-positive cancer stem cells mediate metastasis and
poor clinical outcome in inflammatory breast cancer. Clin Cancer Res
2010, 16(1):45–55.
27. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF,
Orsulic S, et al: Distinct expression levels and patterns of stem cell
marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human
epithelial cancers. PLoS One 2010, 5(4):e10277.
28. Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A,
Foglieni B, Spreafico M, Guerneri S, Baccarin M, et al: Evidence of distinct
tumour-propagating cell populations with different properties in primary
human hepatocellular carcinoma. PLoS One 2011, 6(6):e21369.
29. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM,
Guzman-Ramirez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, et al:
High aldehyde dehydrogenase activity identifies tumor-initiating and
metastasis-initiating cells in human prostate cancer. Cancer Res 2010,
70(12):5163–5173.
30. Buijs JT, van der Horst G, van den Hoogen C, Cheung H, de Rooij B, Kroon J,
Petersen M, van Overveld PG, Pelger RC, van der Pluijm G: The BMP2/7
heterodimer inhibits the human breast cancer stem cell subpopulation
and bone metastases formation. Oncogene 2011, .
31. Marchitti SA, Brocker C, Stagos D, Vasiliou V: Non-P450 aldehyde oxidizing
enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug
Metab Toxicol 2008, 4(6):697–720.
32. Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, Vasiliou V:
Update on the aldehyde dehydrogenase gene (ALDH) superfamily.
Hum Genomics 2011, 5(4):283–303.
33. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der
Pluijm G: The aldehyde dehydrogenase enzyme 7A1 is functionally
involved in prostate cancer bone metastasis. Clin Exp Metastasis 2011,
28(7):615–625.
34. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L,
Leidal A, Gujar S, et al: Aldehyde dehydrogenase activity of breast cancer
stem cells is primarily due to isoform ALDH1A3 and its expression is
predictive of metastasis. Stem Cells 2011, 29(1):32–45.
35. Marchitti SA, Orlicky DJ, Brocker C, Vasiliou V: Aldehyde dehydrogenase
3B1 (ALDH3B1): immunohistochemical tissue distribution and cellular-
specific localization in normal and cancerous human tissues. J Histochem
Cytochem 2010, 58(9):765–783.
36. Marcato P, Dean CA, Giacomantonio CA, Lee PW: Aldehyde
dehydrogenase: its role as a cancer stem cell marker comes down to the
specific isoform. Cell Cycle 2011, 10(9):1378–1384.
37. Zhang Q, Taguchi A, Schliekelman M, Wong CH, Chin A, Kuick R, Misek DE,
Hanash S: Comprehensive proteomic profiling of aldehyde
dehydrogenases in lung adenocarcinoma cell lines. Int J Proteomics 2011,
2011:145010.38. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD,
Mejia PV, Jennings NB, Gershenson DM, et al: Targeting aldehyde
dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010,
12:3186–3199.
39. Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, Lai HC: ALDH1-Bright
Epithelial Ovarian Cancer Cells Are Associated with CD44 Expression,
Drug Resistance, and Poor Clinical Outcome. Am J Pathol 2012,
180(3):1159–1169.
40. Eirew P, Kannan N, Knapp DJ, Vaillant F, Emerman JT, Lindeman GJ, Visvader JE,
Eaves CJ: Aldehyde Dehydrogenase Activity is a Biomarker of Primitive
Normal Human Mammary Luminal Cells. Stem Cells 2012,
30(2):344–348.
41. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL: Differential
expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary
and serous ovarian tumors. J Ovarian Res 2010, 3:28.
42. Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ,
Cairns P, Birrer MJ, Zhang R: ALDH1A1 Is a Novel EZH2 Target Gene in
Epithelial Ovarian Cancer Identified by Genome-Wide Approaches. Cancer
Prev Res (Phila) 2011, 5(3):484–491.
43. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR,
Berkowitz RS, Mok SC, et al: Selenium binding protein 1 in ovarian cancer.
Int J Cancer 2006, 118(10):2433–2440.
44. Manzer R, Qamar L, Estey T, Pappa A, Petersen DR, Vasiliou V: Molecular
cloning and baculovirus expression of the rabbit corneal aldehyde
dehydrogenase (ALDH1A1) cDNA. DNA Cell Biol 2003, 22(5):329–338.
45. Lassen N, Bateman JB, Estey T, Kuszak JR, Nees DW, Piatigorsky J, Duester G,
Day BJ, Huang J, Hines LM, et al: Multiple and additive functions of
ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative
damage in Aldh3a1(−/−)/Aldh1a1(−/−) knock-out mice. J Biol Chem 2007,
282(35):25668–25676.
46. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods
2001, 25(4):402–408.
doi:10.1186/1471-2407-12-329
Cite this article as: Saw et al.: Characterization of aldehyde
dehydrogenase isozymes in ovarian cancer tissues and sphere cultures.
BMC Cancer 2012 12:329.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
